Cediranib
- Generic Name
- Cediranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H27FN4O3
- CAS Number
- 288383-20-0
- Unique Ingredient Identifier
- NQU9IPY4K9
- Background
The novel indole-ether quinazoline Cediranib is a highly potent (IC < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
- Indication
For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-10-05
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1814
- Registration Number
- NCT00384176
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00306891
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath